α-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant.
Richard A Glennon, Mal Gorzata Dukat
ACS Pharmacology & Translational Science December 8, 2023 DOI: 10.1021/acsptsci.3c00139 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Citations | 3 |
| Key findings | Alpha-ethyltryptamine may have been an antidepressant ahead of its time, and its derivatives and optical isomers deserve further investigation. |
Abstract
α-Ethyltryptamine (AET) is quite an interesting, but perhaps long-forgotten, centrally acting agent. Known for more than 75 years, AET was once clinically available as an antidepressant but was withdrawn shortly after its introduction. AET was subsequently controlled as a U.S. Schedule I substance due to its perceived abuse liability and/or toxicity but remains an agent of interest. Hallucinogenic tryptamines (that is, serotonergic psychedelic agents) are now in vogue as novel and exciting chemotherapeutics for the treatment of various neuropsychiatric disorders, including treatment-resistant depression and anxiety. Does AET represent a serotonergic psychedelic agent? Does AET (or its analogs) deserve further investigation? Here, the history of AET is critically reviewed in detail, and an argument is made that AET might have been an agent well ahead of its time. It possesses many of the hallmarks of an antidepressant, suggesting that AET derivatives and particularly their optical isomers are deserving of further investigation.
Citations in the library
Cited by 3
- Modification of natural tryptamines for the treatment of neuropsychiatric diseases Journal of Psychopharmacology October 4, 2025
- Discriminative stimulus properties of α-ethyltryptamine (α-ET) in rats: α-ET-like effects of MDMA, MDA and aryl-monomethoxy substituted derivatives of α-ET. Psychopharmacology June 1, 2025
- Dual Modulation of 5-HT2A Receptors and SERT by α-Ethyltryptamine and Its Optical Isomers. ACS Chemical Neuroscience December 17, 2025
Cites 43
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology & Translational Science December 10, 2020
- Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice Proceedings of the National Academy of Sciences April 13, 2021
- The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects ACS Pharmacology & Translational Science December 10, 2020
and 38 more in the library